干细胞治疗炎症性肠病的安全性及有效性  

Safety and efficacy of stem cell therapy for inflammatory bowel disease

作　　者：王秀 王义国[2] Wang Xiu;Wang Yiguo(Taishan Medical University,Taian 271016,China;Department of Gastroenterology,Qianfoshan Hospital of Shandong Province,Jinan 250014,China)

机构地区：[1]泰山医学院,山东泰安271016 [2]山东省千佛山医院消化内科,济南250014

出　　处：《中华消化病与影像杂志（电子版）》2018年第2期71-75,共5页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

基　　金：济南市科技发展计划(201401097)

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)是一组以复杂的病因和病理生理学改变为基础的疾病,涉及肠道微生物的改变、异常免疫反应、肠上皮细胞和血管系统提供的重要屏障的破坏,并且是一种难以治愈的疾病。药物治疗及手术切除等传统治疗方式存在明显的不足。近年干细胞因其生物学特性开辟了治疗IBD的新型方法。本文就传统方式治疗IBD的不足进行概括,并对干细胞尤其是间充质干细胞移植治疗IBD的安全性、有效性文献进行了回顾总结。Inflammatory bowel disease(IBD)is a group of diseases on the basis of complex etiology and pathophysiology changes involving the changes of intestinal microflora,abnormal immune response,damage of important barrier offered by intestinal epithelial cells and vascular system,and is a kind of incurable disease.There are obvious deficiencies in traditional treatment,such as drug treatment and surgical excision.In recent years,stem cells have opened up a new method for the treatment of IBD because of their biological characteristics.This review summarizes the shortcomings of traditional treatment for IBD,and analyzes the safety and efficacy that stem cells transplantation treats IBD,especially mesenchymal stem cells.

关 键 词：炎症性肠病 间充质干细胞 安全性 有效性 

分 类 号：R574[医药卫生—消化系统]